AR106043A1 - Anticuerpos neutralizantes de poliomavirus - Google Patents

Anticuerpos neutralizantes de poliomavirus

Info

Publication number
AR106043A1
AR106043A1 ARP160102822A ARP160102822A AR106043A1 AR 106043 A1 AR106043 A1 AR 106043A1 AR P160102822 A ARP160102822 A AR P160102822A AR P160102822 A ARP160102822 A AR P160102822A AR 106043 A1 AR106043 A1 AR 106043A1
Authority
AR
Argentina
Prior art keywords
antibody
virus
binding fragment
pharmaceutical composition
antigen
Prior art date
Application number
ARP160102822A
Other languages
English (en)
Spanish (es)
Inventor
Xu Fangmin
Wu Qilong
Wu Danqing
Wang Yongqiang
Wang Lichun
Traggiai Elisabetta
Kovacs Steven
Knapp Mark
Lloyd FEIRE Adam
Dragic Zorica
Abend Johanna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR106043A1 publication Critical patent/AR106043A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
ARP160102822A 2015-09-16 2016-09-16 Anticuerpos neutralizantes de poliomavirus AR106043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2015089764 2015-09-16

Publications (1)

Publication Number Publication Date
AR106043A1 true AR106043A1 (es) 2017-12-06

Family

ID=56936456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102822A AR106043A1 (es) 2015-09-16 2016-09-16 Anticuerpos neutralizantes de poliomavirus

Country Status (23)

Country Link
US (8) US9862760B2 (enExample)
EP (2) EP3350218B1 (enExample)
JP (4) JP7053455B2 (enExample)
CN (2) CN113929771B (enExample)
AR (1) AR106043A1 (enExample)
AU (1) AU2016322814B2 (enExample)
CA (1) CA2995795A1 (enExample)
DK (1) DK3350218T5 (enExample)
ES (1) ES2973856T3 (enExample)
FI (1) FI3350218T3 (enExample)
HR (1) HRP20240413T1 (enExample)
HU (1) HUE065935T2 (enExample)
IL (2) IL296800A (enExample)
LT (1) LT3350218T (enExample)
MX (2) MX392098B (enExample)
PL (1) PL3350218T3 (enExample)
PT (1) PT3350218T (enExample)
RS (1) RS65441B1 (enExample)
SI (1) SI3350218T1 (enExample)
SM (1) SMT202400124T1 (enExample)
TW (2) TWI789744B (enExample)
UY (1) UY36905A (enExample)
WO (1) WO2017046676A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
US10946238B1 (en) 2018-07-23 2021-03-16 Life Fitness, Llc Exercise machines having adjustable elliptical striding motion
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
US12410238B2 (en) 2019-06-19 2025-09-09 Icahn School Of Medicine At Mount Sinai Monoclonal antibodies against JC virus
WO2021236724A2 (en) * 2020-05-20 2021-11-25 Remd Biotherapeutics, Inc. Human endothelin receptor a (etar) antagonist antibodies
MX2022015071A (es) * 2020-06-09 2023-02-27 Memo Therapeutics Ag Moleculas de anticuerpo contra el virus bk.
BR112022025020A2 (pt) * 2020-06-12 2023-02-14 Vera Therapeutics Inc Dosagem de anticorpos neutralizantes de poliomavírus
WO2022094238A2 (en) * 2020-10-29 2022-05-05 Flagship Pioneering Innovations V, Inc. Chicken anemia virus (cav)-based vectors
WO2022152282A1 (zh) * 2021-01-18 2022-07-21 江苏先声药业有限公司 抗人cd22的单克隆抗体及其用途
KR20240006505A (ko) * 2021-03-12 2024-01-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Bk 바이러스에 대한 중화 단클론성 항체
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
CA3254085A1 (en) * 2022-05-18 2023-11-23 The Brigham And Women's Hospital, Inc. KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
CN118725124B (zh) * 2023-03-29 2025-09-16 东莞市朋志生物科技有限公司 抗胃蛋白酶原ⅱ抗体、检测胃蛋白酶原ⅱ的试剂和试剂盒
WO2025111317A1 (en) * 2023-11-21 2025-05-30 The Brigham And Women's Hospital, Inc. Klrb1 binding agents and methods of use thereof
EP4659810A1 (en) 2024-06-07 2025-12-10 Université de Strasbourg Bkv neutralizing antibodies
EP4659811A1 (en) * 2024-06-07 2025-12-10 Université de Strasbourg Bk virus neutralizing antibodies
WO2025252935A1 (en) 2024-06-07 2025-12-11 Universite De Strasbourg Bkv neutralizing antibodies
WO2025252939A1 (en) * 2024-06-07 2025-12-11 Universite De Strasbourg Bk virus neutralizing antibodies
CN119320446B (zh) * 2024-12-02 2026-01-20 上海云泽生物科技有限公司 一种抗bkv抗体及其应用
CN120623324B (zh) * 2025-08-13 2025-10-31 北京溯本源和生物科技有限公司 一种用于bk病毒vp1蛋白检测的单克隆抗体3c7及应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP2298345A3 (en) * 2005-01-24 2012-03-21 MedImmune Limited Specific binding members for NGF
ME03057B (me) * 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
US8080244B2 (en) * 2008-11-21 2011-12-20 Los Alamos National Security, Llc Anti-influenza M2e antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
TW201233686A (en) 2010-12-27 2012-08-16 Japan Health Science Found Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
ES2731757T3 (es) 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
WO2013142300A2 (en) 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
CN104936980B (zh) 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
LT3099713T (lt) * 2014-02-02 2020-07-10 Medimmune Limited Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CA3083363A1 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
MX2022015071A (es) 2020-06-09 2023-02-27 Memo Therapeutics Ag Moleculas de anticuerpo contra el virus bk.
BR112022025020A2 (pt) 2020-06-12 2023-02-14 Vera Therapeutics Inc Dosagem de anticorpos neutralizantes de poliomavírus

Also Published As

Publication number Publication date
US20180079799A1 (en) 2018-03-22
DK3350218T5 (da) 2024-09-30
TWI789744B (zh) 2023-01-11
US10450366B2 (en) 2019-10-22
ES2973856T3 (es) 2024-06-24
IL296800A (en) 2022-11-01
JP2025143348A (ja) 2025-10-01
JP7284790B2 (ja) 2023-05-31
US11161894B2 (en) 2021-11-02
WO2017046676A1 (en) 2017-03-23
LT3350218T (lt) 2024-04-10
AU2016322814B2 (en) 2019-01-24
RS65441B1 (sr) 2024-05-31
EP3350218B1 (en) 2024-02-28
JP2018535648A (ja) 2018-12-06
CN113929771B (zh) 2024-08-27
JP7053455B2 (ja) 2022-04-12
SI3350218T1 (sl) 2024-05-31
US12077571B2 (en) 2024-09-03
EP3350218A1 (en) 2018-07-25
US20230399382A1 (en) 2023-12-14
CN108026166A (zh) 2018-05-11
JP2023071881A (ja) 2023-05-23
US20220363735A1 (en) 2022-11-17
CN108026166B (zh) 2021-10-08
IL257541A (en) 2018-04-30
JP2022002524A (ja) 2022-01-11
HRP20240413T1 (hr) 2024-07-19
US10435460B2 (en) 2019-10-08
US20190002533A1 (en) 2019-01-03
DK3350218T3 (da) 2024-04-02
EP4414385A3 (en) 2024-10-30
IL257541B (en) 2022-11-01
TWI726911B (zh) 2021-05-11
US10654914B2 (en) 2020-05-19
US20250051423A1 (en) 2025-02-13
TW202200611A (zh) 2022-01-01
PT3350218T (pt) 2024-03-27
TW201722987A (zh) 2017-07-01
FI3350218T3 (fi) 2024-03-22
UY36905A (es) 2017-04-28
AU2016322814A1 (en) 2018-03-29
US20170088605A1 (en) 2017-03-30
MX392098B (es) 2025-03-21
SMT202400124T1 (it) 2024-05-14
CA2995795A1 (en) 2017-03-23
MX2022005253A (es) 2022-06-29
CN113929771A (zh) 2022-01-14
US20200190167A1 (en) 2020-06-18
JP7706489B2 (ja) 2025-07-11
MX2018003282A (es) 2018-05-16
US11639378B2 (en) 2023-05-02
US9862760B2 (en) 2018-01-09
EP4414385A2 (en) 2024-08-14
IL257541B2 (en) 2023-03-01
HUE065935T2 (hu) 2024-06-28
PL3350218T3 (pl) 2024-08-12
US20190071488A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
AR106043A1 (es) Anticuerpos neutralizantes de poliomavirus
Carugati et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis
FI3536710T3 (fi) Anti-il-36r -vasta-aineita
EA201690182A1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА КОМПЛЕМЕНТА C1q И ИХ ПРИМЕНЕНИЯ
JP2020536488A5 (enExample)
Merad et al. An aberrant inflammatory response in severe COVID-19
RU2015111563A (ru) Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
PE20181046A1 (es) Anticuerpos anti-tigit y metodos de uso
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
CL2018003407A1 (es) Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
AR108663A1 (es) ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
HRP20200881T1 (hr) Antitijela koja vežu beta-klotho domenu 2 i postupci njihove uporabe
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
RU2017107773A (ru) Антитела, специфичные к ммр9
Won et al. Significance of isoagglutinin titer in ABO‐incompatible kidney transplantation
BR112015021979A2 (pt) Anticorpos humanos para grem1
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
Hendrikx et al. Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice
WO2017014679A3 (en) Humanized monoclonal antibody specific to syndecan-1
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh

Legal Events

Date Code Title Description
FB Suspension of granting procedure